|

Pemigatinib Clinical Trials

11 actively recruiting trials across 4 locations

Also known as: INCB054828, PEMAZYRE, Pemazyre, Pemazyre®

Other6 trials

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
Phase 2
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells
Phase 2
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
Phase 2
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Birmingham, Alabama2 trials

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

Ohio State University-Telemedicine

Phase 2
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

University of Alabama at Birmingham

Phase 2

Boston, Massachusetts1 trial

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Massachusetts General Hospital

Phase 1

Portland, Oregon1 trial

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

OHSU Knight Cancer Institute

Phase 1

Salt Lake City, Utah1 trial

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Huntsman Cancer Institute at University of Utah

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.